Wockhardt Stock Gains Today After Report of Success of New Drug Zaynich

Mumbai, July 28, 2025 – Wockhardt Ltd (NSE: WOCKPHARMA) surged over 4% on Monday morning as investors responded to its antibiotic Zaynich® being featured in a UK journal for successfully treating a drug-resistant antibiotic infection.

Zaynich , combining Zidebactam and Cefepime, showed clinical success in a U.S. liver transplant patient unresponsive to other treatments. Zaynich has cleared Phase III trials globally.

At 11:10 a.m. today, 28th July, the stock is up by 2.3% at Rs 1,713.

Key Market Data

As of 10:36 AM IST on July 28, Wockhardt was trading at ₹1,728.70, up ₹51.20 or 3.05% from the previous close. The stock reached an intraday high of ₹1,775.00, with a turnover of ₹143.81 crore and a delivery volume of 32.64%.

Breakthrough in Antimicrobial Resistance Treatment

In a press release issued under Regulation 30 of SEBI LODR, Wockhardt announced that its proprietary antibiotic Zaynich® was featured in the Journal of Antimicrobial Chemotherapy – AMR, a prestigious UK-based medical journal. The article highlights the successful treatment of a critically ill U.S. liver transplant patient with a pan-drug resistant infection unresponsive to conventional antibiotics like cefiderocol and eravacycline.

“Within 11 days of treatment with Zaynich®, the patient showed clinical improvement and was shifted from ICU to the general ward. Follow-up scans confirmed the infection was resolved, making the transplant successful,” the company stated.

Zaynich®, developed in-house by Wockhardt, is a combination of Zidebactam and Cefepime. It recently completed pivotal Phase III trials globally and has been used under compassionate use programs for over 50 patients in the U.S. and India. The antibiotic targets extensively drug-resistant Gram-negative infections and has shown efficacy where other drugs have failed.

Global Recognition and Pipeline

Wockhardt has a robust antibiotic discovery pipeline with six candidates in development, three of which already have clinical approvals. All compounds have secured Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA.

Outlook

Zaynich’s clinical success strengthens Wockhardt’s positioning in antibiotic innovation. The market is reading this as validation of its R&D pipeline. Sustained traction could depend on regulatory progress, expanded use cases, and commercial rollout in key resistance-burdened geographies.

About the Company

Wockhardt Limited is a listed pharmaceutical and biotechnology company with manufacturing and R&D operations in India, UK, and Ireland. With a presence in over 20 countries, ~77% of the company’s global revenue is derived from international markets. The company is part of the NIFTY Smallcap 250 index and operates across the pharmaceutical spectrum with a focus on antimicrobial resistance and novel antibiotic development.

REF: https://nsearchives.nseindia.com/corporate/WOCKPHARMA_28072025090145_PressReleasefinal28072025sd.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations